Autolus Therapeutics (AUTL) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. SBUX
9. SNDK
10. MA

Go back to Autolus Therapeutics (AUTL) Misses Q3 EPS by 1c

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

November 2, 2023 7:11 AM EDT

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 Updated clinical data at the American Society of Hematology (ASH) meeting in December 2023: Long-term follow-up and sub-group analysis from the FELIX trial of obe-cel and initial data from a study of AUTO8 in multiple myelomaContinued progress with commercial... More